Glenmark Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) to evaluate antivirial drug favipiravir in clinical trials to treat patients with Covid-19.To get more news about Favipiravir, wisepowder official website is the best place for you.

Favipiravir is a generic version of Fujifilm Toyama Chemical's influenza drug Avigan, which holds approval in Japan for treating new influenza virus infections.Glenmark developed the drug's API and formulations internally. Following the regulatory approval, the new trial will assess the product in Covid-19 patients with mild to moderate infection.

Around 150 patients will be enrolled for the study. Participants will be given favipiravir plus standard supportive care or only standard supportive care.Treatment duration of the trial is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomisation.

Glenmark Pharmaceuticals Global R&D executive vice-president Sushrut Kulkarni said: "After having successfully developed the API and the formulations through its in-house R&D team, Glenmark is all geared to immediately begin clinical trials on favipiravir on Covid-19 patients in India.

"The clinical trial will let us know the efficacy of this molecule on Covid-19 patients. If the clinical trials are successful, favipiravir could become a potential treatment for Covid-19 patients."Last month, Fujifilm initiated a Phase II study of Avigan (favipiravir) to treat Covid-19 patients in the US. The trial will evaluate the drug's safety and efficacy as a potential Covid-19 therapy.

The company also commenced a Phase III trial of Avigan for the treatment of Covid-19 patients in Japan.In addition to treatment studies for Covid-19, Fujifilm is working to boost the production of Avigan to help fight the pandemic.

The drug is produced and distributed upon request by the government of Japan. Avigan was never distributed in the market and is not available at hospitals and pharmacies in Japan or internationally.

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused coronavirus disease 2019 (COVID-19) has been reported in China since December 2019. More than 16% of patients developed acute respiratory distress syndrome, and the fatality ratio was about 1%-2%. No specific treatment has been reported. Herein, we examine the effects of Favipiravir (FPV) versus Lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19. To get more news about 259793-96-9, wisepowder official website is the best place for you.
Patients with laboratory-confirmed COVID-19 who received oral FPV (Day 1: 1600 mg twice daily; Days 2-14: 600 mg twice daily) plus interferon (IFN)-α by aerosol inhalation (5 million U twice daily) were included in the FPV arm of this study, whereas patients who were treated with LPV/RTV (Days 1-14: 400 mg/100 mg twice daily) plus IFN-α by aerosol inhalation (5 million U twice daily) were included in the control arm. Changes in chest computed tomography (CT), viral clearance, and drug safety were compared between the two groups. For the 35 patients enrolled in the FPV arm and the 45 patients in the control arm, all baseline characteristics were comparable between the two arms. A shorter viral clearance time was found for the FPV arm versus the control arm (median (interquartile range, IQR), 4 (2.5-9) d versus 11 (8-13) d, P < 0.001).
The FPV arm also showed significant improvement in chest imaging compared with the control arm, with an improvement rate of 91.43% versus 62.22% (P = 0.004). After adjustment for potential confounders, the FPV arm also showed a significantly higher improvement rate in chest imaging. Multivariable Cox regression showed that FPV was independently associated with faster viral clearance. In addition, fewer adverse reactions were found in the FPV arm than in the control arm. In this open-label nonrandomized control study, FPV showed significantly better treatment effects on COVID-19 in terms of disease progression and viral clearance; if causal, these results should be important information for establishing standard treatment guidelines to combat the SARS-CoV-2 infection.

Appili Therapeutics has secured regulatory clearance from Health Canada to move ahead with a phase 2 study for studying FUJIFILM Toyama Chemical's favipiravir as a preventative measure against the outbreak of novel coronavirus (Covid-19).To get more news about 259793-96-9, wisepowder official website is the best place for you.

e Canadian biopharma company expects to immediately begin recruitment for the mid-stage trial of favipiravir with an aim to enroll nearly 760 subjects from both residents and staff across 16 long-term care homes (LTCHs) in Ontario, Canada.

Allison McGeer, a senior clinician scientist at Sinai Health's Toronto-based Lunenfeld-Tanenbaum Research Institute will be the primary investigator of the phase 2 trial.

Allison McGeer said: "Given the severity of COVID-19 amongst the elderly, and the evidence of ongoing transmission with severe outcomes in LTCHs, it is critical to develop interventions that minimize the spread of disease in this setting. As vaccines and treatment for COVID-19 remain unavailable, we must explore all possible solutions.

"We look forward to working with Appili on this study, as the pandemic continues to present devastating consequences for LTCH residents and their families."

Designed as a broad-spectrum antiviral, favipiravir is approved in Japan under the Avigan brand name. Japanese health authorities granted approval in 2014 for FUJIFILM Toyama Chemical to use Avigan as a treatment and stockpile countermeasure for outbreaks of pandemic influenza.

According to Appili Therapeutics, the primary goal of its phase 2 clinical trial is to assess the efficacy of favipiravir for 25 days compared with placebo as prophylaxis against Covid-19 outbreaks in LTCHs.

The mid-stage trial's primary endpoint will be control of the outbreak which is defined as no new cases of Covid-19 in residents for 24 consecutive days up to Day 40 after the start of prophylaxis.Among the secondary objectives are measures of safety, infection rates, disease progression, and also fatality rates.

Appili Therapeutics chief medical officer Yoav Golan said: "With the strikingly high fatality rate from COVID-19 in long-term care facilities, there is a particularly urgent need to protect our most vulnerable members of society.

"Preventing and controlling COVID-19 outbreaks in long-term care facilities is therefore of extreme importance."Industry and academia are coming together in unprecedented ways to mitigate this crisis, and Appili is proud to be part of this unique collaboration."

The antiviral drug Favipiravir, better known as Avigan, is being trialed as a treatment for the novel coronavirus disease (COVID-19). Avigan is the brand name of the drug Favipiravir, it was developed by the Japanese Fujifilm Toyama Chemical Company, has emerged as a potential drug to treat patients infected with the deadly novel coronavirus.To get more news about 259793-96-9, wisepowder official website is the best place for you.

Two renowned pharmaceutical industries of Bangladesh have manufactured this drug in their plant for the trial of COVID-19 patients in Bangladesh. Other pharmaceutical industries are also in the process of getting permission to produce the drug from the Directorate General of Drug Administration (DGDA), Bangladesh.

In Japan, Favipiravir was approved in 2014 for sale domestically under the brand name Avigan for stockpiling against influenza pandemics. Testing in the development stages, however, revealed that the drug can result in elevated blood uric acid levels and cause deformities in the unborn young of animals.

This anti-influenza drug has shown some promise in the fight against COVID-19, but experts warn that it has known side effects and that there is insufficient clinical data for its use. Favipiravir works by blocking the ability of a virus to replicate inside a cell. It induces lethal RNA transversion mutations, producing a nonviable viral phenotype.

Favipiravir is a prodrug that is metabolised to its active form, favipiravir-ribofuranosyl-5-triphosphate, available in both oral and intravenous formulations. It does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them.
However, Favipiravir has not proven effective in primary human airway cells, casting doubt on its efficacy in influenza treatment. Japan approved favipiravir for treating influenza strains unresponsive to current antivirals. The Japanese Fujifilm Toyama Chemical Company initially hoped that favipiravir would become a new influenza medication that could replace oseltamivir (brand name Tamiflu).

On the other hand, animal experiments show the potential for teratogenic effects, and the approval of production by the Ministry of Health, Labor and Welfare was greatly delayed and the production condition is limited only in an emergency in Japan.

The Italian Pharmaceutical Agency, however, has reminded the public that the existing evidence in support of this drug is scant and preliminary Favipiravir has shown limited efficacy against the Zika virus in animal studies, but was less effective than other antivirals such as MK-608. The agent has also shown some efficacy against rabies and has been used experimentally in some humans infected with the virus.

A study of 80 people in comparison to ritonavir found that it reduced viral clearance time and that 91% of people had improved Computed Tomography (CT) scans with few side effects. The limitation of this study was that it was not randomised, double-blinded and placebo-controlled.

The drug has been approved for use in clinical trials of the novel coronavirus disease 2019 in China and at the same time, in March 2020, Italy also has approved the drug for experimental use against COVID-19 and has begun conducting trails in three regions most affected by the disease. Though this drug is on the trial process and in some cases on phase II or III, this drug could be a light of hope for the treatment of COVID-19 until we get a better option.

The novel coronavirus swept across China around January 20, with the Chinese New Year celebration underway. By late March, as U.S. schools were just beginning to shut down, Chinese schools had already been closed for about 10 weeks-and some were beginning to reopen.To get more news about China business school, you can visit acem.sjtu.edu.cn official website.

The education sector was squarely in the middle of China's fight against COVID and the after effects continue to be felt: In early April, the government announced it would delay important exams, including the gaokao, the university entrance exam in China.

In a webinar recently hosted by EdSurge, with support from school networking platform ClassIn, Chinese school leaders shared their insights and lessons learned. Based on that dialogue, as well as other research (including this guide developed by Beijing Normal University and UNESCO), we've pulled together some early lessons learned from China's experience.

Because of the very close relationship between the Chinese government and industry, China took some unique actions. Even so, here are some observations about what Chinese educators discovered as they tried to keep learning going remotely.

1. The Government's Role: Decisive, Sweeping Policy Changes

Few countries have central governments that literally call the shots for the private sector. China does. Since January, officials made many big decisions about when schools and education companies would open or close, and what resources were available to support learning.

China's Ministry of Education (MOE) issued school closure policies for the entire country between January 20 and February 8, affecting China's 278 million students across primary and postsecondary grades. Wuhan, the epicenter of the epidemic, was locked down on January 23. Tutoring centers and daycares closed. The central government suggested K-12 and higher-ed delay starting the new semester and postpone any regional and national exams.

But along with shutting down bricks and mortar schools, China also beefed up two existing virtual ones. One platform, Empower Learning, was built by the government, in collaboration with China's seven largest edtech companies, offering digital K-12 curriculum. The platform provides live streaming courses that students can tap into from their phone or computer at home. The MOE also created its own site: Educloud. This site features videos, teaching plans and communities of the best teachers' lessons recorded over the past eight years.

Although both platforms existed before the COVID crisis to provide free online learning resources to students, they added scheduling tools to help educators select and share materials with students and widely circulated them to the public once the schools closed.

After February 8, the MOE worked with provincial education departments to pick dates for reopening schools. Although not all schools opened at the same time, the government sent clear signals about changes. In addition, in late March, the MOE announced it would delay the university entrance exam, the gaokao, for a month.

"Welded Wire Mesh Panel Market" research report offers the breakdown of the industry by market size, rate of development, key companies, counties, product selections and application. The Welded Wire Mesh Panel Market Report delivers current state, openings, limits, drivers and also the evolution forecasts of the market by 2025. Profound investigation about Welded Wire Mesh Panel market standing, enterprise competition outline, welfares and drawbacks of enterprise stock, Welded Wire Mesh Panel industry development trends, regional industrial layout features and economics policies, industry News and Strategies by Regions has additionally been enclosed.To get more news about metal grid panels, you can visit boegger.net official website.

Welded Wire Mesh Panel is a kind of prefabricated connection grid of electrofusion welding, which consists of a series of parallel longitudinal wires with precise spacing welded to the required spacing of cross wires.

In Regional Analysis, the Welded Wire Mesh Panel market is also categorised into North America, Europe, China, Japan, the middle East, India, South America, Others. North America, Europe is expected to account for a distinguished share, in terms of price and extent, of the Welded Wire Mesh Panel market throughout the forecast length. The Welded Wire Mesh Panel market within the Asia Pacific is projected to extend throughout the forecast period. Evolving markets that include China and Asian country are expected to play a significant position within the boom in producing the surrounding area.
Welded Wire Mesh Panel market report provides in-depth data about company Profiles, Welded Wire Mesh Panel launching and Market Positioning, their Production, Value, Price, ratio and Target Customers. Research report contains data about following major players in Welded Wire Mesh Panel market, which strategically profile the key players and comprehensively analyse their growth strategies and market segmentation:

The In-depth industry chain includes analysis value chain analysis, porter five forces model analysis and cost structure analysis. This Welded Wire Mesh Panel Market report describes present situation, historical background and future forecast. It Comprehensive data showing Welded Wire Mesh Panel sale, consumption, trade statistics, and prices in the recent years are provided. The Welded Wire Mesh Panel report indicates a wealth of information on Welded Wire Mesh Panel vendors. Welded Wire Mesh Panel Market forecast for next five years, including Market volumes and prices is also provided. Raw Material Supply and Downstream Consumer Information is also included.

At last, report on Welded Wire Mesh Panel Market is a comprehensive analysis of the Market providing you with the latest industry data and future Market trends. The facts and information in the report will allow you to identify significant factors in the Market which are products, revenue, and growth cost-effectiveness. However, it is expected that there will be a remarkable growth in the demand of Welded Wire Mesh Panel Market from 2020 to 2025.

The 3rd China International Import Expo (CIIE) concluded in Shanghai on Nov. 10. Some 400,000 professional visitors have registered to attend the expo, making it one of the largest events in the world in 2020.To get more news about CIIE 2020 shanghai, you can visit shine news official website.

Unlike the first two events, this year's expo is being held amid the COVID-19 pandemic. Jinbao, the mascot of the expo, is seen wearing a giant blue mask. Anti-epidemic measures are implemented throughout the exhibition area, and people are reminded to wear masks and practice social distancing.

The Medical Equipment & Health Care Products area, one of the six exhibition areas this year, has witnessed the greatest number of new product and service launches, with a record number of 340 exhibitors participating.

The area has also set up a 12,000-square-meter zone dedicated to public health and epidemic prevention, where over 98% of the world's industry leaders are showcasing their cutting-edge products, technologies, and services. Many are used or will be used in the global fight against COVID-19.

For example, Noah I, an imaging diagnosis solution developed by GE Healthcare, was once used at some temporary hospitals and designated treatment centers in Wuhan. It was then scaled up to be used on the frontlines of the global fight against COVID-19 in places like France and Turkey.

This year has been quite rough for many companies, yet their enthusiasm for the expo has not been dampened by the pandemic.

According to the organizers, US$72.62 billion worth of tentative deals were reached for one-year purchases of goods and services at this year's expo, up 2.1% over the previous year.

This year's event is very different from the previous two, but China's commitment to further opening up and international cooperation has not changed.